usa flag
OTC:MYNDF
canada flag CSE:MYND

SPONSORED

As Mental Health Deteriorates Worldwide, The Estimated $28.6 Billion Antidepressant Market Looks Long Overdue for a Revolution(1)

MYND Life Sciences , For Example, Could Help Transform the Treatment of Major Depressive Disorder for Approx. 264 Million People Around the World(2)

Press Release September 29, 2021
MYND Life Sciences Inc. Announces RSU Grant

Worldwide, mental health is on the decline.

Nearly 264 million people are struggling with depression, for example.(2)

While some of us may be better at hiding our depression than others, it can be a real struggle, especially with the potential anxiety, irritability, and hopelessness.

Robin Williams, for example, spent his life making people laugh themselves silly while dealing with issues of severe depression.(3) A dear friend of mine who always has a smile on her face in public often wants to be left alone, struggling with depression for years.

Many even “put on a face” so others aren’t aware of how they really feel.

It’s not fun. It’s not easy.

Besides, it often gets old telling people, “I’m okay,” when we’re not.

To help alleviate the symptoms of depression, many turn to anti-depressants such as SSRIs (selective serotonin reuptake inhibitors).(4) About 13% of Americans age 12+ are currently on medications to help reduce those symptoms.(4) The problem is — SSRIs aren’t always helpful, focusing more on symptom suppression than the root cause.(4)

Making matters worse, over the last 20 years, we’ve seen very little innovation with SSRIs. (3)

According to The Guardian, “The number of psychopharmacological drugs research programs in larger drug firms has shrunk by 70% in the past decade.”(5)

“In general the larger companies have walked away from psychiatry,” they noted. “There are a few companies who have maintained efforts in the area but 70% tells you it’s been a pretty remarkable departure. Many withdrew from neuroscience entirely.”(5)

Of course, that needs to change.

That being said, the pharmaceutical industry is overdue for a massive, game-changing revolution when it comes to mental health care.

Fortunately, that revolution may have already begun thanks to companies like MYND Life Sciences Canada CSE: (MYND) U.S. OTC: (MYNDF).

With the help of MYND Life Sciences and psi-lo-cybin, approximately 264 million people all around the world could be offered a new way to deal with their depression.

The Top Reasons to Consider MYND Life Sciences Canada CSE: (MYND) U.S. OTC: (MYNDF) Now

  1. With global mental health deteriorating, the roughly $28.6 billion antidepressant market could be long overdue for sweeping, revolutionary changes.(1)
  2. Right now, about 264 million people are struggling with depression worldwide.(2)
  3. To help deal with depression, many turn to antidepressants such as SSRIs (selective serotonin reuptake inhibitors).(4)
  4. About 13% of Americans aged 12+ are currently on medications, such as Zol-of-t or Pro-za-c, to help reduce the symptoms of depression.(4)
  5. Unfortunately, many SSRIs focus more on symptom suppression than the root cause. Worse, over the last 20 years, we’ve seen very little innovation with SSRIs.(4)
  6. With the help of MYND Life Sciences Canada CSE: (MYND) U.S. OTC: (MYNDF) and psi-lo-cybin, these approximately 264 million patients may have a new innovative way to treat their major depressive disorder.
  7. Currently, MYND is planning for several clinical trials to establish the efficacy of its novel diagnostics and therapeutics, with plans to rapidly commence these in Q4 of 2021.(4)
  8. The company is approaching a clinical trial to address a novel marker for diagnosing and monitoring, both qualitatively and quantitatively, depression in response to psi-lo-cybin treatment and various psych-e-delics.(4)
  9. It’s also nearing a clinical trial to address the therapeutic impact of psi-lo-cybin and psi-lo-cybin analogs as anti-inflammatories in diminishing the cytokine storm related to today’s health predicament.(4)
  10. MYND is also nearing a clinical trial to address the therapeutic impact of psi-lo-cybin and psi-lo-cybin analogs on depression in patients with confirmed health predicament-related conditions.(4)

Just Who is MYND Life Sciences Canada CSE: (MYND) U.S. OTC: (MYNDF)?

MYND is a life sciences drug development company that’s aggressively advancing psi-lo-cybin-based medicines to help treat mental illness. The company’s MYND-604 treatment is being developed to treat major depressive disorder (MDD) and bring much-needed innovation to the antiquated multi-billion dollar SSRI market.

Helping, 2021 could be a game-changing year for the company.

At the moment, MYND is planning for several clinical trials to establish the efficacy of its novel diagnostics and therapeutics with plans to rapidly commence these in Q4 of 2021: (4)

  • A clinical trial to address a novel marker for diagnosing and monitoring, both qualitatively and quantitatively, depression in response to psi-lo-cybin treatment as well as various psych-e-delics.
  • A clinical trial to address the therapeutic impact of psi-lo-cybin and psi-lo-cybin analogs as anti-inflammatories in diminishing cytokine storm related to today’s health predicament.
  • A clinical trial to address the therapeutic impact of psi-lo-cybin and psi-lo-cybin analogs on depression in patients with confirmed health predicament-related conditions.
  • A clinical trial to address the therapeutic effect of psi-lo-cybin with sepsis.

Its MYND-604 program for MDD, for example, is being developed to treat MDD and bring much-needed innovation to the antiquated multi-billion dollar SSRI market.(4)

Additionally, MYND-778 is being developed as an oral dosage form of psi-lo-cybin for the treatment of sepsis. Sepsis is a bi-phasic inflammatory disease characterized by an initial hyper-inflammatory phase called systemic inflammatory response syndrome (SIRS), which is followed by an anti-inflammatory phase called endotoxin tolerance (ET).(4)

Are Psych-e-delics, Like Psi-lo-cybin Useful with Mental Health Issues?

It sure looks that way.

For one, the US FDA is backing research into psi-lo-cybin.  In 2018, for example, the agency recognized psi-lo-cybin as “breakthrough therapy” for depression.(6)

Two, clinical studies from the likes of Johns Hopkins and New York University are already showing positive results.

  • A study from JAMA Psychiatry just found that psi-lo-cybin “worked better than the usual antidepressant medications,” as noted by NPR.(7)
  • Johns Hopkins Medicine launched the Center for Psych-e-delic and Consciousness Research to study psi-lo-cybin and other compounds to treat mental health problems, such as anorexia, addiction and depression.(8)
  • A study in the journal, NaturePsi-lo-cybin for treatment-resistant depression: fMRI-measured brain mechanisms – showed that 47% of treatment-resistant patients with depression showed positive responses five weeks after psi-lo-cybin treatments.(9)
  • New York University found that “Psi-lo-cybin produced immediate, substantial, and sustained improvements in anxiety and depression and led to decreased cancer-related demoralization and hopelessness, improved spiritual well-being.”(10)
  • The Beckley Foundation said, “Psi-lo-cybin was well-tolerated and induced rapid and lasting reduction in the severity of depressive symptoms.”(11)

Major cities in Colorado, California, Michigan, Oregon, and Washington D.C. have decriminalized ent-he-ogens and taken significant strides for legal psych-e-delic assisted therapy.(4)

In Canada, Health Canada allowed four terminal cancer patients to undergo end-of-life care with psi-lo-cybin. Plus, healthcare professionals nationwide have been approved for professional training using psi-lo-cybin.(4)

Not to mention, “As patents on many conventional antidepressants begin to expire – and public and regulatory opinion regarding psych-e-delics is changing – 2021 will be the time that psych-e-delic therapy casts a spotlight on the limitations of current mental-health care treatments, and highlights a bold alternative,” according to Wired UK.(12)

Strong Management, Strong Results – MYND Life Sciences Canada CSE: (MYND) U.S. OTC: (MYNDF)

MYND Life Sciences Canada CSE: (MYND) U.S. OTC: (MYNDF) was founded by Dr. Wilfred Jefferies and Dr. Lyle Oberg with the goal of improving mental health.

Dr. Jefferies is a world-renowned Neuro-immunologist with over 60 patents and 100 publications in prestigious medical journals, including Nature and The Lancet. Through research conducted by Dr. Jeffries over the past 30 years and Dr. Oberg’s executive leadership, the two intend to establish the link between depression and inflammation in the brain. All with the ultimate goal to develop a pharmaceutical treatment utilizing compounds found in psi-lo-cybin.

Dr. Wilfred Jefferies, Co-Founder and Chief Science Officer

Dr. Wilfred A. Jefferies earned his Doctor of Philosophy degree from the Sir William Dunn School of Pathology at the University of Oxford, followed by post doctorates at top academic centres in Switzerland and Sweden. He was quickly recognized as a rising star by none other than Nobel Prize laureate Dr. Michael Smith who personally recruited him to his laboratory at the University of British Columbia where he continues to perform research today. Dr. Jefferies is recognized as a leader in the emerging field of immunotherapy and his research has resulted in new and innovative ways to use components of the body’s own immune system to fight cancer, viruses and even promote brain health. He has an uncanny ability to translate complex immunological breakthroughs into real world medical treatments.

Dr. Jefferies is also a member of the UBC Departments of Microbiology & Immunology, Medical Genetics, and Zoology, as well as the Centre for Blood Research and the Djavad Mowafaghian Centre for Brain Health.

Dr. Lyle Oberg, Co-Founder and Chief Executive Officer

A physician by profession, Dr. Oberg possesses extensive senior leadership, finance and corporate governance experience. He was first elected to the Legislative Assembly of Alberta as a Progressive Conservative in 1993. He was first appointed to the Alberta Cabinet in 1997 and served numerous posts. He launched a western Canadian initiative to address Fetal Alcohol Syndrome and implemented an interprovincial strategy to share resources and develop new and better approaches for addressing FAS. In May 1999, Dr. Oberg was appointed Minister of Learning, He began the second language initiative in Alberta schools to give students an edge in the world marketplace and initiated the development of the daily physical activity program to improve the health of Alberta students. In 2006, Lyle Oberg was named Minister of Finance. Lyle left politics in 2008 with one of the largest surpluses in Alberta history. Dr. Oberg later opened and became CEO of C2DNA, the first private DNA testing facility in Canada.

Jordan Cleland, Chief Operating Officer

Jordan Cleland is the Chief Operating Officer of MYND Life Sciences. He previously operated Jordan Cleland Consulting, a communications, public relations, fundraising, leadership coaching and strategy practice. Cleland formerly served as Vice President, Advancement at Olds College in  Alberta, Canada where he maximized reputation and relationships with media, alumni, donors, prospective students and governments. Jordan was presented the Gold Medal for Excellence in Leadership at the 2013 Colleges and Institutes Canada conference.Cleland earned a Master’s in Leadership through Otago Polytechnic in New Zealand and a Bachelor of Arts in Political Science from Whitworth University in Washington. He furthered his management and communications expertise in attaining certificates from York University, University of British Columbia and Harvard/MIT. Prior roles were with the Workers’ Compensation Board, KPMG Consulting and in the senior levels of government as a Ministerial Chief of Staff with the Government of Alberta.

Scientific Advisory Board
Dr. Mark Geyer

Mark A. Geyer Ph.D. is Distinguished Professor of Psychiatry and Neurosciences Emeritus at the University of California San Diego (UCSD) and directs the Neuropsychopharmacology Unit of the VISN 22 Veterans Administration Mental Illness Research, Clinical, and Education Center. At UCSD, he is a founding member of the Consortium for Translational Research in Neuropsychopharmacology (CTRIN) and Translational Research in Psychophysiology, Exploration, and Cognition (TRIPEC) groups. In 1993, he co-founded the Heffter Research Institute, which pioneered and supported much of the scientific research that has prompted the exploration of psych-e-delics as potential therapeutics in humans. He has recently co-founded the Psych-e-delics and Health Research Initiative at UCSD, which is exploring the efficacy of psych-e-delics in the treatment of pain disorders.

Dr. Joseph Martin

Joseph Boyd Martin, M.D., Ph.D., Edward R. and Anne G. Lefler Professor of Neurobiology, served as Dean of the Harvard Faculty of Medicine from 1997 to 2007. Born in Bassano, Alberta, Canada in 1938, Dr. Martin received his premedical and medical education at the University of Alberta, Edmonton, earning the M.D. degree in 1962. He completed a residency in neurology in 1966 and fellowship in neuropathology in 1967 at Case Western Reserve University in Cleveland, Ohio, and received his Ph. D. in anatomy from the University of Rochester in 1971. Dr. Martin began his career in academic medicine at McGill University in Montreal, where he eventually became Chair of the Department of Neurology and Neurosurgery in 1977. In 1978, he joined the faculty of Harvard Medical School in Boston as the Bullard Professor of Neurology and Chief of the Neurology service at the Massachusetts General Hospital. In 1984, he was appointed the Julieanne Dorn Professor of Neurology at Harvard. Dr. Martin’s research focused on hypothalamic regulation of pituitary hormone secretions and on application of neurochemical and molecular genetics to better understand the causes of neurological and neurodegenerative disease.

Dr. Michael Brownstein

Dr. Brownstein has over thirty years of research experience in the fields of genetics, endocrinology and pharmacology. He earned his bachelor’s degree from Columbia University; completed his graduate training at University of Chicago, where he earned an M.D. and Ph.D. in pharmacology; and received his clinical training at the Boston Children’s Hospital. He then moved to the National Institutes of Health to work with Julius Axelrod, recipient of a Nobel Prize in 1970 for his studies in the field of neuropharmacology, and remained at NIH after completing his fellowship. Dr. Brownstein served at the NIH as Chief of the Laboratory of Genetics of the National Institute of Mental Health and the National Human Genome Research Institute; and for two years as the Scientific Director of the NIMH Intramural Research Program.

John Trowsdale

John Trowsdale is an Emeritus Professor, specialist in Immunogenetics, in the Department of Pathology, University of Cambridge UK. In the early 1980’s he was one of the first to clone HLA genes and to complete sequencing of the entire HLA region. In collaboration with Stephan Beck at the Sanger Centre he provided sequenced common HLA haplotypes, which were used as ‘gold-standard’ references. John’s interest in GenDx is in further development of rapid genetic analysis of highly variable genes such as HLA and KIR in human disease, such as infection, autoimmunity, cancer and pregnancy disorders. The link with GenDx is of mutual benefit in driving forward the use of next generation sequencing techniques to achieve rapid and accurate immunogenetic analysis. John visits GenDx to discuss how development of novel techniques at GenDx benefits the research and health care communities.

The Top Reasons to Consider MYND Life Sciences Canada CSE: (MYND) U.S. OTC: (MYNDF) Now

  1. With global mental health deteriorating, the roughly $28.6 billion antidepressant market could be long overdue for sweeping, revolutionary changes.(1)
  2. Right now, about 264 million people are struggling with depression worldwide.(2)
  3. To help deal with depression, many turn to antidepressants such as SSRIs (selective serotonin reuptake inhibitors).(4)
  4. About 13% of Americans aged 12+ are currently on medications, such as Zol-of-t or Pro-za-c, to help reduce the symptoms of depression.(4)
  5. Unfortunately, many SSRIs focus more on symptom suppression than the root cause. Worse, over the last 20 years, we’ve seen very little innovation with SSRIs.(4)
  6. With the help of MYND Life Sciences Canada CSE: (MYND) U.S. OTC: (MYNDF) and psi-lo-cybin, these approximately 264 million patients may have a new innovative way to treat their major depressive disorder.
  7. Currently, MYND is planning for several clinical trials to establish the efficacy of its novel diagnostics and therapeutics, with plans to rapidly commence these in Q4 of 2021.(4)
  8. The company is approaching a clinical trial to address a novel marker for diagnosing and monitoring, both qualitatively and quantitatively, depression in response to psi-lo-cybin treatment and various psych-e-delics.(4)
  9. It’s also nearing a clinical trial to address the therapeutic impact of psi-lo-cybin and psi-lo-cybin analogs as anti-inflammatories in diminishing the cytokine storm related to today’s health predicament.(4)
  10. MYND is also nearing a clinical trial to address the therapeutic impact of psi-lo-cybin and psi-lo-cybin analogs on depression in patients with confirmed health predicament-related conditions.(4)
Source 1: https://bit.ly/3stmdI8
Source 2: https://www.who.int/news-room/fact-sheets/detail/depression
Source 3: https://acl.gov/news-and-events/acl-blog/robin-williams-raising-awareness-about-depression
Source 4: MYND investor deck
Source 5: https://bit.ly/3sx9G6v
Source 6: https://bit.ly/3su0EqL
Source 7: https://n.pr/3x6gr2C
Source 8: https://bit.ly/3gh6JEC
Source 9: https://www.nature.com/articles/s41598-017-13282-7
Source 10: https://bit.ly/3sw4pMj
Source 11: https://on.mktw.net/32rGK57
Source 12: https://bit.ly/2QDiZEJ

Legal Disclaimer


This website / media webpage is owned, operated and edited by TD Media LLC. Any wording found on this website / media webpage or disclaimer referencing to “I” or “we” or “our” or “TD Media” refers to TD Media LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote small public companies. By reading our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our website / media webpage.We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website / media webpage are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. TD Media business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our Websites, Email, SMS, Push Notifications, Influencers, Social Media Postings, Ticker Tags, Press Releases, Online Interviews, Podcasts, Videos, Audio Ads, Banner Ads, Native Ads, Responsive Ads. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, TD Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.

INFLUENCER COMPENSATION

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 05/26/2021 and ending on 05/26/2021 to publicly disseminate information about (MYNDF:US) (MYND:CA) via digital communications. We have paid this Influencer one thousand dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 05/27/2021 and ending on 05/27/2021 to publicly disseminate information about (MYNDF:US) (MYND:CA) via digital communications. We have paid this Influencer eight hundred fifty dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 06/01/2021 and ending on 06/03/2021 to publicly disseminate information about (MYNDF:US) (MYND:CA) via digital communications. We have paid this Influencer five hundred dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 06/01/2021 and ending on 06/01/2021 to publicly disseminate information about (MYNDF:US) (MYND:CA) via digital communications. We have paid this Influencer four hundred twenty five dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 06/02/2021 and ending on 06/02/2021 to publicly disseminate information about (MYNDF:US) (MYND:CA) via digital communications. We have paid this Influencer five hundred dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 06/02/2021 and ending on 06/04/2021 to publicly disseminate information about (MYNDF:US) (MYND:CA) via digital communications. We have paid this Influencer seven hundred dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 06/02/2021 and ending on 06/02/2021 to publicly disseminate information about (MYNDF:US) (MYND:CA) via digital communications. We have paid this Influencer one thousand five hundred dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 06/03/2021 and ending on 06/03/2021 to publicly disseminate information about (MYNDF:US) (MYND:CA) via digital communications. We have paid this Influencer five hundred dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 06/03/2021 and ending on 06/03/2021 to publicly disseminate information about (MYNDF:US) (MYND:CA) via digital communications. We have paid this Influencer one thousand one hundred fifty dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 06/03/2021 and ending on 06/03/2021 to publicly disseminate information about (MYNDF:US) (MYND:CA) via digital communications. We have paid this Influencer five hundred dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 06/04/2021 and ending on 06/04/2021 to publicly disseminate information about (MYNDF:US) (MYND:CA) via digital communications. We have paid this Influencer five hundred dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 06/07/2021 and ending on 06/07/2021 to publicly disseminate information about (MYNDF:US) (MYND:CA) via digital communications. We have paid this Influencer one thousand five hundred forty five dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 09/20/2021 and ending on 09/24/2021 to publicly disseminate information about (MYNDF:US) (MYND:CA) via digital communications. We have paid this Influencer eight hundred dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 09/20/2021 and ending on 09/24/2021 to publicly disseminate information about (MYNDF:US) (MYND:CA) via digital communications. We have paid this Influencer one thousand dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 09/27/2021 and ending on 10/01/2021 to publicly disseminate information about (MYNDF:US) (MYND:CA) via digital communications. We have paid this Influencer one thousand dollars USD.

COMPENSATION

Pursuant to an agreement between TD Media LLC and Winning Media LLC, TD Media LLC has been hired for a period beginning on 05/26/2021 and ending on 05/27/2021 to publicly disseminate information about (MYNDF:US) (MYND:CA) via digital communications. We have been paid sixteen thousand dollars USD via bank wire transfer.

Pursuant to an agreement between TD Media LLC and Winning Media LLC, TD Media LLC has been hired for a period beginning on 05/28/2021 and ending on 09/30/2021 to publicly disseminate information about (MYNDF:US) (MYND:CA) via digital communications. We have been paid an additional one hundred forty four thousand dollars USD via bank wire transfer. We own zero shares of (MYNDF:US) (MYND:CA). To date we have been paid one hundred sixty thousand dollars USD via bank wire transfer. To disseminate information about (MYNDF:US) (MYND:CA) via digital communications.

(Last updated: 1635228185 unix)

Company Contact

Address: 733 Finns Road
KelownaBC V1X 5B7Canada
Phone:
1.780.965.0122

E-Mail: [email protected]
Web: http://www.myndsciences.com

Company Description

MYND is a life sciences drug development company that’s aggressively advancing psi-lo-cybin-based medicines to help treat mental illness. The company’s MYND-604 treatment is being developed to treat major depressive disorder (MDD) and bring much-needed innovation to the antiquated multi-billion dollar SSRI market.